Evidence map›Paper›PMID 39105788›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis.

Sandra Michaela Ihne-Schubert, Caroline Morbach, Vladimir Cejka, Maximilian Johannes Steinhardt, Aikaterini Papagianni, Stefan Frantz, Hermann Einsele, Thomas Wehler, Klaus Martin Kortüm, Claudia Sommer and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sandra Michaela Ihne-SchubertInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany. ihne_s@ukw.de.ORCID http://orcid.org/0000-0001-8540-7122
Caroline MorbachInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Vladimir CejkaInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Maximilian Johannes SteinhardtInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Aikaterini PapagianniInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Stefan FrantzInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Hermann EinseleInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Thomas WehlerDepartment of Internal Medicine IV, University Hospital Gießen and Marburg, Gießen, Germany.
Klaus Martin KortümInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Claudia SommerInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Stefan StörkInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.
Torben SchubertCIRCLE - Centre for Innovation Research, Lund University, Lund, Sweden.
Andreas GeierInterdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital of Würzburg, Würzburg, Germany.

Funding

Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg Z-2_CSP-08
6 · The paper itself

Abstract

BACKGROUND/

aimsCongestion is prognostically relevant in cardiac transthyretin amyloidosis (ATTR-CA), but whether congestion has an incremental prognostic value beyond the well-established, congestion-sensitive NT-proBNP is unknown. Therefore, we aimed to comparatively evaluate the prognostic utility of several congestion surrogates over NT-proBNP.

methodsWe estimated hazard ratios by Cox proportional hazards regressions with time-varying covariates from a panel data set of the local amyloidosis cohort study AmyKoS. Different models were compared by using chi(χ) RESULTS/

conclusion131 ATTR-CA patients (wild-type 84.0%, hereditary 6.9%, without genetic testing 9.2%; median age 78.7 (quartiles 73.3, 82.1) years; 85.5% male) with 566 observations across a median follow-up of 38.2 (30.6; 48.2) months were analyzed. 83.2% received disease-modifying treatment; 20.6% participated concurrently in placebo-controlled gene silencer trials. Information on congestion improved biomarker-driven risk stratification and identified patients at the highest risk. Echocardiographic congestion markers performed better than clinical findings and daily diuretic use/dosage. Relevant adjusters were daily diuretic dosage, disease-modifying treatment, eGFR, and right atrial volume. NT-proBNP and the tricuspid regurgitation peak velocity (tr-v

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesNatriuretic Peptide, BrainPeptide FragmentsAgedAged, 80 and overBiomarkersEchocardiographyFemaleFollow-Up StudiesHumansMalePrognosisRisk AssessmentBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)ATTR amyloidosisCardiac amyloidosisCongestionDiureticsNT-proBNPRisk stratificationTricuspid regurgitation peak velocity (tr-vmax)

Identifiers

PMID39105788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.